Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

19.2% of patients on Islatravir-Lenacapavir experienced mild adverse events, like dry mouth and nausea. The data was presented at the ID Week 2024. At 48 weeks, the investigational combination ...

US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead plans to supply lenacapavir to generic manufacturers, priced at no-profit to the company, until they fully support demand. The agreements also cover lenacapavir for HIV prevention that is ...